智飞生物：上半年亏损5.97亿元

Core Viewpoint - The company reported a significant decline in revenue and incurred a net loss in the first half of 2025, attributed to decreased public vaccination willingness and changing market demand [1] Financial Performance - The company achieved an operating revenue of 4.919 billion yuan in the first half of 2025, representing a year-on-year decrease of 73.06% [1] - The net profit attributable to the parent company was a loss of 597 million yuan, compared to a net profit of 2.234 billion yuan in the same period last year [1]